Department of Immunology, Health in Code, A Coruña, Galicia, Spain.
Genetics Division, Universitary Hospital Marqués de Valdecilla, Santander, Canatabria, Spain.
Front Immunol. 2023 Oct 9;14:1279171. doi: 10.3389/fimmu.2023.1279171. eCollection 2023.
At present, the knowledge about disease-causing mutations in IRF2BP2 is very limited because only a few patients affected by this condition have been reported. As previous studies have described, the haploinsufficiency of this interferon transcriptional corepressors leads to the development of CVID. Very recently, a more accurate phenotype produced by truncating variants in this gene has been defined, manifesting CVID with gastrointestinal inflammatory symptoms and autoimmune manifestations.
We analyzed 5 index cases with suspected primary immunodeficiency by high throughput sequencing. They were submitted for a genetic test with a panel of genes associated with immune system diseases, including IRF2BP2. The screening of SNVs, indels and CNVs fulfilling the criteria with very low allelic frequency and high protein impact, revealed five novel variants in IRF2BP2. In addition, we isolated both wild-type and mutated allele of the cDNA from one of the families.
In this study, we report five novel loss-of-function (LoF) mutations in IRF2BP2 that likely cause primary immunodeficiency, with CVID as more frequent phenotype, variable expression of inflammatory gastrointestinal features, and one patient with predisposition of viral infection. All identified variants were frameshift changes, and one of them was a large deletion located on chromosome 1q42, which includes the whole sequence of IRF2BP2, among other genes. Both and dominant modes of inheritance were observed in the families here presented, as well as incomplete penetrance.
We describe novel variants in a delimited low-complex region, which may be considered a hotspot in IRF2BP2. Moreover, this is the first time that a large CNV in IRF2BP2 has been reported to cause CVID. The distinct mechanisms than LoF in IRF2BP2 could cause different phenotype compared with the mainly described. Further investigations are necessary to comprehend the regulatory mechanisms of IRF2BP2, which could be under variable expression of the disease.
目前,关于 IRF2BP2 致病突变的知识非常有限,因为只有少数患有这种疾病的患者被报道。如前所述,这种干扰素转录核心抑制剂的杂合子功能缺失会导致 CVID 的发生。最近,在该基因中截短变异所导致的更准确表型已被定义,表现为伴有胃肠道炎症症状和自身免疫表现的 CVID。
我们通过高通量测序分析了 5 例疑似原发性免疫缺陷的索引病例。他们接受了与免疫系统疾病相关基因的基因检测,包括 IRF2BP2。筛选具有极低等位基因频率和高蛋白影响的符合标准的 SNVs、indels 和 CNVs,揭示了 IRF2BP2 中的五个新变体。此外,我们从一个家庭中分离出野生型和突变型 cDNA。
本研究报告了 IRF2BP2 中的五个新的失活(LoF)突变,这些突变可能导致原发性免疫缺陷,以 CVID 为更常见的表型,炎症性胃肠道特征的可变表达,以及一名患者易发生病毒感染。所有鉴定的变体均为移码变化,其中一个位于 1q42 上的大片段缺失,包括 IRF2BP2 的整个序列,以及其他基因。在本研究中呈现的家族中观察到和显性遗传模式以及不完全外显率。
我们描述了限定低复杂度区域的新变体,该区域可能被视为 IRF2BP2 的热点。此外,这是首次报道 IRF2BP2 中的大片段 CNV 导致 CVID。IRF2BP2 中的不同机制与主要描述的 LoF 相比可能导致不同的表型。需要进一步研究来了解 IRF2BP2 的调控机制,这可能导致疾病的可变表达。